Crohn's disease and its particularities: a literature review
DOI:
https://doi.org/10.33448/rsd-v12i5.41923Keywords:
Crohn's disease; Inflammatory bowel disease; Diarrhea.Abstract
Crohn's disease is an inflammatory disease of the gastrointestinal tract with a multifactorial etiology. Based on the severity of Crohn's Disease and the effect it causes on patients' quality of life, this paper aims to discuss its main clinical aspects, involving diagnosis and better professional management. A literature review was carried out with data collection through a bibliographic review for secondary surveys in the PUBMED, SCIELO and LILACS online databases. The incidence of Crohn's Disease (CD) between females and males is similar, ranging from 15 to 40 years old. It has the highest number of cases in Europe, North America and South America. There are several classifications for Crohn's Disease, and therefore it is the health professional's responsibility to know them, in order to know how to distinguish and carry out the correct drug prescription and treatment. Therefore, it is imperative that you are aware of the main characteristics, such as symptoms, etiology and preventive methods.
References
Akobeng, A. K., Steinhart, A. H., & Gardener, E. (2002). Oral 5‐aminosalicylic acid for maintenance of remisssion in Crohn's Disease. Cochrane Database of Systematic Reviews, (2).
Beaugerie, L., & Sokol, H. (2012). Clinical, serological and genetic predictors of inflammatory bowel disease course. World journal of gastroenterology: WJG, 18(29), 3806.
Bell, S. J., Williams, A. B., Wiesel, P., Wilkinson, K., Cohen, R. C. G., & Kamm, M. A. (2003). The clinical course of fistulating Crohn's disease. Alimentary pharmacology & therapeutics, 17(9), 1145-1151.
Dignass, A., Van Assche, G., Lindsay, J. O., Lémann, M., Söderholm, J., Colombel, J. F., ... & Travis, S. P. L. (2010). The second European evidence-based consensus on the diagnosis and management of Crohn's disease: current management. Journal of Crohn's and Colitis, 4(1), 28-62.
Doherty, G., Bennett, G., Patil, S., Cheifetz, A., & Moss, A. C. (2009). Interventions for prevention of post‐operative recurrence of Crohn's disease. Cochrane Database of Systematic Reviews, (4).
Egan, L. J., Sandborn, W. J., & Tremaine, W. J. (1998). Clinical outcome following treatment of refractory inflammatory and fistulizing Crohn's disease with intravenous cyclosporine. The American journal of gastroenterology, 93(3), 442-448.
Ferreira, G. S., de Deus, M. H. A., & Junior, E. A. (2021). Fisiopatologia e etiologias das doenças inflamatórias intestinais: uma revisão sistemática de literatura Pathophysiology and etiologies of the inflammatory bowel diseases: a systematic review. Brazilian Journal of Health Review, 4(4), 17061-17076.
Feagan, B. G., Rochon, J., Fedorak, R. N., Irvine, E. J., Wild, G., Sutherland, L., ... & McDonald, J. W. (1995). Methotrexate for the treatment of Crohn's disease. New England Journal of Medicine, 332(5), 292-297.
Ford, A. C., Kane, S. V., Khan, K. J., Achkar, J. P., Talley, N. J., Marshall, J. K., & Moayyedi, P. (2011). Efficacy of 5-aminosalicylates in Crohn's disease: systematic review and meta-analysis. Official journal of the American College of Gastroenterology| ACG, 106(4), 617-629.
Fumery, M., Singh, S., Dulai, P. S., Gower-Rousseau, C., Peyrin-Biroulet, L., & Sandborn, W. J. (2018). Natural history of adult ulcerative colitis in population-based cohorts: a systematic review. Clinical Gastroenterology and Hepatology, 16(3), 343-356.
Gaburri, P. D., Castro, L. E. V. V. D., Ferreira, J. O. D., Lopes, M. H. M., Ribeiro, A. M. B., Alves, R. A., ... & Chelbi, J. M. F. (1998). Epidemiologia, aspectos clínicos e evolutivos da doença de Crohn: um estudo de 60 casos. Arq. gastroenterol, 240-6.
Hanauer, S. B., Sandborn, W., & Practice Parameters Committee of the American College of Gastroenterology. (2001). Management of Crohn's disease in adults. Official journal of the American College of Gastroenterology| ACG, 96(3), 635-643.
Hanauer, S. B., & Strömberg, U. (2004). Oral Pentasa in the treatment of active Crohn’s disease: a meta-analysis of double-blind, placebo-controlled trials. Clinical Gastroenterology and Hepatology, 2(5), 379-388.
Iskandar, H. N., & Ciorba, M. A. (2012). Biomarkers in inflammatory bowel disease: current practices and recent advances. Translational Research, 159(4), 313-325.
Lichtenstein, G. R., Hanauer, S. B., Sandborn, W. J., & Practice Parameters Committee of the American College of Gastroenterology. (2009). Management of Crohn's disease in adults. Official journal of the American College of Gastroenterology| ACG, 104(2), 465-483.
Ng, W. K., Wong, S. H., & Ng, S. C. (2016). Changing epidemiological trends of inflammatory bowel disease in Asia. Intestinal research, 14(2), 111.
Matsuoka, K., Kobayashi, T., Ueno, F., Matsui, T., Hirai, F., Inoue, N., ... & Shimosegawa, T. (2018). Evidence-based clinical practice guidelines for inflammatory bowel disease. Journal of gastroenterology, 53(3), 305-353.
Malchow, H., Ewe, K., Brandes, J. W., Goebell, H., Ehms, H., Sommer, H., & Jesdinsky, H. (1984). European Cooperative Crohn's Disease Study (ECCDS): results of drug treatment. Gastroenterology, 86(2), 249-266.
Mendes, K. D. S., Silveira, R. C. D. C. P., & Galvão, C. M. (2008). Revisão integrativa: método de pesquisa para a incorporação de evidências na saúde e na enfermagem. Texto & contexto-enfermagem, 17, 758-764.
Oliveira, F. M., do Carmo Emerick, A. P., & Soares, E. G. (2010). Epidemiology aspects of inflammatory bowel disease in the east region of Minas Gerais State. Ciência & saúde coletiva, 15, 1031.
Sabate, J. M., Villarejo, J., Lemann, M., Bonnet, J., Allez, M., & Modigliani, R. (2002). An open‐label study of thalidomide for maintenance therapy in responders to infliximab in chronically active and fistulizing refractory Crohn's disease. Alimentary pharmacology & therapeutics, 16(6), 1117-1124.
Sandborn, W. J., Feagan, B. G., Hanauer, S. B., Lochs, H., Löfberg, R., Modigliani, R., ... & Sutherland, L. R. (2002). A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. Gastroenterology, 122(2), 512-530.
Sandborn, W. J., Rutgeerts, P., Enns, R., Hanauer, S. B., Colombel, J. F., Panaccione, R., ... & Pollack, P. F. (2007). Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Annals of internal medicine, 146(12), 829-838.
Santos, A. L. C., Oliveira Dias, B. C., Silva, K. A., & Sales Ferreira, J. C. (2021). Terapia nutricionais nas doenças inflamatórias intestinais: Doença de Crohn e Retocolite Ulcerativa. Research, Society and Development, 10(7), e11410716660-e11410716660.
Singleton, J. W., Hanauer, S. B., Gitnick, G. L., Peppercorn, M. A., Robinson, M. G., Wruble, L. D., ... & Pentasa Crohn's Disease Study Group. (1993). Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Gastroenterology, 104(5), 1293-1301.
Souza, M. H. L., Troncon, L. E. D. A., Rodrigues, C. M., Viana, C. F., Onofre, P. H., Monteiro, R. A., ... & Meneghelli, U. G. (2002). Evolução da ocorrência (1980-1999) da doença de Crohn e da retocolite ulcerativa idiopática e análise das suas características clínicas em um hospital universitário do sudeste do Brasil. Arquivos de Gastroenterologia, 39, 98-105.
Souza, M. M. D., Belasco, A. G. S., & Aguilar-Nascimento, J. E. D. (2008). The epidemiological profile of patients with inflammatory Bowel disease in the State of Mato Grosso. Revista Brasileira de Coloproctologia, 28, 324-328.
Stein, R. B., & Lichtenstein, G. R. (2001). Medical therapy for Crohn's disease: the state of the art. Surgical Clinics of North America, 81(1), 71-101.
Summers, R. W., Switz, D. M., Sessions Jr, J. T., Becktel, J. M., Best, W. R., Kern Jr, F., & Singleton, J. W. (1979). National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology, 77(4), 847-869.
Targan, S. R., Hanauer, S. B., Van Deventer, S. J., Mayer, L., Present, D. H., Braakman, T., ... & Rutgeerts, P. J. (1997). A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn's disease. New England Journal of Medicine, 337(15), 1029-1036.
Thia, K. T., Sandborn, W. J., Harmsen, W. S., Zinsmeister, A. R., & Loftus Jr, E. V. (2010). Risk factors associated with progression to intestinal complications of Crohn's disease in a population-based cohort. Gastroenterology, 139(4), 1147-1155.
Travis, S. P. L., Stange, E. F., Lémann, M., Öresland, T., Chowers, Y., Forbes, A., ... & Mortensen, N. J. (2006). European evidence based consensus on the diagnosis and management of Crohn’s disease: current management. Gut, 55(suppl 1), i16-i35.
Venito, L., Santos, M. S. B., & Ferraz, A. R. (2022). Doença de Crohn e retocolite ulcerativa. Revista Eletrônica Acervo Saúde, 15(7), e10667-e10667.
Vermeire, S., Schreiber, S., Sandborn, W. J., Dubois, C., & Rutgeerts, P. (2010). Correlation between the Crohn's disease activity and Harvey–Bradshaw indices in assessing Crohn's disease severity. Clinical Gastroenterology and Hepatology, 8(4), 357-363.
Zhulina, Y., Udumyan, R., Tysk, C., Montgomery, S., & Halfvarson, J. (2016). The changing face of Crohn’s disease: a population-based study of the natural history of Crohn’s disease in Örebro, Sweden 1963–2005. Scandinavian Journal of Gastroenterology, 51(3), 304-313.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Gonçalo da Silva Feitosa Neto; Iangla Araújo de Melo Damasceno
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
